XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2

GENERAL (Details) - USD ($) $ in Thousands		1 Months Ended
	Aug. 05, 2013	Mar. 30, 2018	Jun. 30, 2020
GENERAL [Abstract]
Upfront payment received	$ 10,000	$ 10,000
Development, regulatory and commercial milestones compensation		$ 200,000
Potential milestone compensation	250,000
Preclinical milestone compensation	$ 23,000
Amount of investment in Compugen			$ 12,000

X

- Definition

Development, regulatory and commercial milestones compensation.

+ References

No definition available.

+ Details

Name:	cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation
Namespace Prefix:	cgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.

+ References

No definition available.

+ Details

Name:	cgen_ResearchAndDevelopmentArrangementPaymentsReceivable
Namespace Prefix:	cgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.

+ References

No definition available.

+ Details

Name:	cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
Namespace Prefix:	cgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Nominal or face amount on the investment owned.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 10
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6438156&loc=d3e57880-113973

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 10
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6431724&loc=d3e32938-113948

+ Details

Name:	us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration